Published in Clin Mol Hepatol on March 28, 2016
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS One (2016) 0.85
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World J Gastroenterol (2016) 0.75
Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. Biomed Res Int (2017) 0.75
Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol (2016) 0.75
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver (2017) 0.75
New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75
Effect of Korean Red Ginseng in chronic liver disease. J Ginseng Res (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Management of hepatocellular carcinoma: an update. Hepatology (2011) 33.57
Hepatocellular carcinoma. Lancet (2003) 22.54
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg (1995) 3.04
Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol (2009) 2.16
Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol (2010) 2.00
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol (2010) 1.69
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology (2000) 1.64
Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer (2012) 1.38
Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther (2006) 1.00
Small heterodimer partner attenuates profibrogenic features of hepatitis C virus-infected cells. Liver Int (2015) 1.43
[Three cases of multiple infarcted regenerative nodules in liver cirrhosis after gastrointestinal hemorrhage]. Korean J Hepatol (2008) 0.93
Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med (2014) 0.91
Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients. Gut Liver (2016) 0.84
Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. Gut Liver (2017) 0.81
Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol (2015) 0.78
A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol (2016) 0.78
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult. Clin Mol Hepatol (2015) 0.76
Undifferentiated embryonal sarcoma in adult liver. Korean J Pathol (2014) 0.76
Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients? Clin Mol Hepatol (2016) 0.75
Is the environment of the endoscopy unit a reservoir of pathogens? Intest Res (2014) 0.75
Improved severe hepatopulmonary syndrome after liver transplantation in an adolescent with end-stage liver disease secondary to biliary atresia. Clin Mol Hepatol (2014) 0.75
Management of portal hypertensive gastropathy and other bleeding. Clin Mol Hepatol (2014) 0.75
Current status and strategies for hepatitis B control in Korea. Clin Mol Hepatol (2017) 0.75
Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis. J Gastroenterol Hepatol (2017) 0.75
Serum cystatin C level is an excellent predictor of mortality in patients with cirrhotic ascites. J Gastroenterol Hepatol (2017) 0.75
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver (2017) 0.75
[Removal of Choledocholith by Endoscopic Retrograde Cholangiopancreatography in a Situs Invsersus Patient]. Korean J Gastroenterol (2015) 0.75
[A case of acute myocardial infarction occurred immediately after endoscopic submucosal dissection]. Korean J Gastroenterol (2010) 0.75
Can Patient Education with a Smartphone Application Improve the Quality of Bowel Preparation for Colonoscopy? Clin Endosc (2017) 0.75
Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology (2017) 0.75